ArticleJournal of surgical oncology2026
Recurrence of Giant Cell Tumor of Bone and Related Risk Factors: A Retrospective Analysis of 340 Cases From a Single Center.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recurrence of Giant Cell Tumor of Bone and Related Risk Factors: A Retrospective Analysis of 340 Cases From a Single Center.Journal of surgical oncology · 2026Article
- Tumor-associated osteoclasts converge on a matrix-sulfation program across human bone tumors.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell tumor of bone (GCTB) is a locally aggressive bone tumor, with recurrence being its major clinical complication. Surgery remains the primary treatment modality, and numerous factors may influence the risk of recurrence. This study aimed to retrospectively analyze the incidence of local recurrence of GCTB and the related risk factors in a single-center cohort. PATIENTS AND
methodsA total of 340 patients with benign GCTB treated at our center between 2002 and March 2023 were retrospectively reviewed, including 172 males and 168 females. The mean age was 34.04 ± 12.83 years (range, 13-78 years). In 48.2% of patients, tumors were located in the distal femur or proximal tibia. Surgical procedures consisted of extended curettage and wide resection. All the patients were followed up with a minimum duration of 24 months.
resultsThe overall recurrence rate was 20.00%, with a mean recurrence interval of 21.90 ± 14.57 months (range, 3-67 months). Multivariable Cox regression analysis demonstrated that surgical type and sex were independent risk factors for recurrence-free survival. The recurrence rate following extended curettage was 22.55%, significantly higher than that following wide resection (9.23%) (HR, 4.75; 95% CI, 2.02 to 11.19; p < 0.001). Male patients had a recurrence rate of 15.12%, significantly lower than that of female patients (25.00%) (HR, 0.53; 95% CI, 0.32 to 0.87; p = 0.01). In the extended curettage group, female sex and Campanacci grade Ⅲ were identified as recurrence risk factors.
conclusionsTumor recurrence may develop in approximately one-fifth of the patients who underwent surgical treatment of GCTB. Extended curettage was independent risk factors for the local recurrence. Specifically, for the extended curettage group, patients with Campanacci grade III are recommended with closer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.